Increasing Research and Capacity to End Malaria in Africa

Malaria is a complex disease with an intricate web of interactions involving the Plasmodium parasite, a female Anopheles mosquito and a susceptible human. As explored in previous webinars of the End Malaria series by the Platform for Dialogue and Action on Health Technologies in Africa (Health Tech Platform), there is no one-size-fits-all solution for eliminating the disease. 

Each setting demands a multifaceted and comprehensive approach, considering the whole lifecycle of transmission (from mosquitoes to humans) and backed by robust health systems, policies, and community engagement. In this blog, we explore how Africa’s research and technical capacity can support the delivery of this comprehensive approach.

While delivering her keynote speech, Prof. Faith Osier, Co-Director of the Institute of Infection and Chair of Malaria Immunology and Vaccinology at Imperial College London, emphasised that a comprehensive and system-wide approach is essential if we stand any chance of eliminating malaria. Asymptomatic malaria keeps the disease alive and perpetuates its transmission. 

Therefore, while it is crucial to concentrate research and development efforts on population groups such as children under the age of five years that are most vulnerable to malaria, countries must consider tools and interventions that involve multiple academic disciplines to address its transmission across the entire population, seeking out the asymptomatic malaria infections to completely eliminate the disease.

Investing in a diverse research environment

A diverse and multidisciplinary research environment is critical to inform policy and programme implementation. As highlighted by Dr Susan Imbahale, Senior Lecturer at Technical University of Kenya, the success of higher learning institutions in producing quality malaria research encompasses the entire research environment, including infrastructure, multidisciplinary collaboration, and government support. The current research landscape therefore needs to move from individual research projects to large-scale, multidisciplinary endeavours to address the complexity inherent in eliminating the disease. 

To this end, sustainable and adequate funding to institutions of higher learning is essential to support long-term malaria control efforts in Africa. Furthermore, creating effective incentives, beyond financial rewards, can motivate researchers to continue producing impactful work that addresses real-world challenges. This involves strengthening research infrastructure by establishing state-of-the-art laboratories and research centres, ensuring they are well-equipped to conduct innovative research on malaria control and elimination. 

This innovation is necessary, according to Dr Donnie Mategula, Deputy Group Head, Infectious Disease Epidemiology Group at Malawi Liverpool Wellcome Programme. Mainstay malaria interventions deployed over the past decade need to be updated to address emerging threats such as climate change and malaria vectors which are spreading beyond their range limits. Innovations through research would consider the heterogeneity of transmission within locales, and maximise the effective delivery of existing malaria control tools while providing new tools to supplement current elimination efforts. 

Dr Sessinou Benoit Assogba, a Postdoctoral Research Scientist at the London School of Hygiene & Tropical Medicine further noted that a core focus should be on investing in the training, mentorship and empowerment of young scientists who will serve as catalysts for ground-breaking innovations that can reshape the landscape of disease control. Enabling young minds to develop and implement novel malaria control strategies bolsters local capacity and resilience, driving positive change from within communities.

Research-to-policy infrastructure

Research findings should ideally directly inform policy decisions. However, while research organisations generate a substantial amount of evidence, there is a notable lack of effective translation of this data into policy and legislative action to support malaria elimination. Bridging the gap between research and policy implementation remains a critical concern. This can be achieved by enabling a supportive environment that encourages the flow of information and utilisation of research findings from academic to government corridors. 

Prof. Charles Mbogo, a public health entomologist, Chief Research Scientist, and President of the Pan-African Mosquito Control Association (PAMCA) expounded that the elimination of malaria should be treated as a development issue, and not just as a health problem. This would allow African governments to establish broader mechanisms in relation to malaria interventions, for instance including considerations of urban housing and irrigation schemes.

African governments should also have mechanisms in place to foster collaboration among researchers, between researchers and national malaria control programmes, and with international partners. This will facilitate the exchange of knowledge, resources, and expertise – technical and non-technical, and accelerate the reinvention and development of tools and strategies for malaria control that considers local contexts and challenges.

Ultimately, the responsibility of malaria eliminations lies with Africans whose continent bears the greatest burden of the disease. Enhancing the African research and technical capacity expands the tool box for malaria control, and it is through united action that we can harness the power of research, advocacy, policy, and public awareness to end the burden of malaria on the continent.

Read summaries of the previous webinars:

Webinar 1 Zero Malaria Is Possible: Ending the Malaria Burden in Africa

Webinar 2 Navigating Africa’s Journey to Malaria Elimination: Threats and Opportunities

Webinar 3 Closing the Gap in Financing Malaria Control Strategies

Webinar 4 Advancing Malaria Elimination with Emerging Health Technologies

Advancing Malaria Elimination with Emerging Health Technologies

Previous episodes of AFIDEP’s End Malaria webinar series, hosted by its Platform for Dialogue and Action on Health Technologies in Africa, established that the journey towards eliminating malaria faces not only a host of challenges and threats but also opportunities that, if well integrated into current intervention efforts, Africa and the world can eliminate malaria. One of these opportunities is leveraging emerging health technologies in malaria control. This blog explores various innovative approaches and technologies that hold promise to revolutionise malaria control in Africa – vaccines, monoclonal antibodies, gene drives and artificial intelligence.

Vaccines

The development of an effective malaria vaccine has long been a goal in the fight against the disease. The World Malaria Report 2022 notes that significant progress has been made in research and development since the initial release of the malaria vaccine Preferred Product Characteristics (PCCs) in 2014. After a decades-long journey to create a vaccine, the World Health Organization (WHO), in October 2021, recommended the first malaria vaccine, RTS,S/AS01, to be given to children from age 5 months in moderate-to-high transmission settings to curb malaria infections.

The RTS,S/AS01 demonstrated effectiveness as a P. falciparum malaria vaccine during phase 3 clinical trials, proving to be at least as efficient as seasonal malaria chemoprevention in children while maintaining a satisfactory safety and tolerability record. There are a number of malaria vaccines currently in clinical development that targets different phases of the parasite’s life cycle, including its presence in the liver and the blood.

Speaking on the deployment of the vaccine in Kenya, Dr Rose Jalango, Head of Kenya’s National Vaccines and Immunization Program at the Ministry of Health, highlighted that approved malaria vaccines are best deployed through subnational immunisation programmes, focusing on areas with a high burden of the disease, to ensure widespread and targeted availability. In Kenya, the vaccine is delivered through the Kenya Expanded Programme on Immunization infrastructure in efforts to ensure broader access to immunisation.

Monoclonal antibodies

Monoclonal antibodies have emerged as tools to treat cancer, autoimmune and inflammatory disorders. Clinical trials underway for malaria have shown promising results, demonstrating their potential efficacy in reducing infection rates. These antibodies are engineered to target specific components of the malaria parasite, such as proteins on the surface of infected red blood cells, to neutralise the parasite, prevent its replication, and potentially reduce disease severity.

Dr Neville Kisalu, Program Advisor at PATH’s Center for Vaccine Innovation and Access, noted that different emerging tools for malaria control face their own unique challenges. For monoclonal antibodies, the high cost of production requires developing cost-effective production methods and ensuring accessibility for the populations most affected by malaria. Nevertheless, they could serve as complementary measures in malaria interventions, for instance, passive immunisation with monoclonal antibodies could supplement vaccines, especially for seasonal malaria immunoprevention.

Gene drives

Gene drive technology encompass processes in which an organism is engineered to bias the inheritance of desired traits from parent to offspring through sexual reproduction. The process allows for the rapid spread of desirable genetic traits through generations. In the context of malaria control, scientists are exploring gene drive technology to engineer mosquitoes with reduced ability to transmit the malaria parasite (population replacement), or to reduce the overall malaria mosquito population (population suppression).

Dr Brian Tarimo, Research Scientist at Ifakara Health Institute, noted that the promise of gene drive technology is that it could transcend the logistical challenges other malaria control tools face. He, however, emphasised that this promise needs to include risk assessments, regulatory mechanisms, and community engagement if it is to be deployed as a complementary tool for malaria elimination.

Artificial intelligence

Lastly, artificial intelligence (AI) is increasingly being leveraged in various fields of healthcare, and malaria control is no exception. AI technologies, such as machine learning and data analytics, can play a crucial role in predicting malaria outbreaks, facilitating drug discovery, and improving diagnostic accuracy. Further, AI-powered mobile applications can identify malaria hotspots and optimise interventions for maximum impact.

Artificial intelligence in malaria control and elimination can serve as an enabler for current and emerging tools by providing cost and time savings for more effective deployment of interventions, as explained by Aloyce Urassa, Chairperson of ALMA’s Youth Advisory Council.

Challenges and future directions

Despite the immense promise of these technologies to eliminate malaria, several challenges need to be addressed for their successful deployment in malaria-endemic regions. These include increasing capacity for research and development, reducing the cost of production, and creating robust healthcare infrastructure to facilitate their distribution and administration. 

In his keynote speech, Dr Fredros Okumu, Director of Science at the Ifakara Health Institute, emphasised that transforming malaria control requires building local leadership for public health research and practice. He further underscored that it is crucial to keep the private sector and manufacturers engaged in developing and improving control strategies. Collaboration between research and production mechanisms can lead to the development of new tools and technologies that are more effective and suitable for the African context.

Another prerequisite to transforming malaria control through emerging technologies, as highlighted by Dr Okumu, is improving the quality and use of data at national and subnational levels. Currently, many countries rely heavily on global data, and a more data-driven approach within countries can allow them to tailor their malaria responses to specific local contexts.

In conclusion, while some of these technologies show promise as standalone interventions, their true potential lies in their integration with existing malaria control measures; deploying them alongside frontline tools and strategies can create a comprehensive and multifaceted approach to malaria elimination. The synergy between these interventions can maximise the impact of malaria control efforts and accelerate progress towards eliminating the disease.

Read summaries of the previous webinars:

Webinar 1 Zero Malaria Is Possible: Ending the Malaria Burden in Africa

Webinar 2 Navigating Africa’s Journey to Malaria Elimination: Threats and Opportunities

Webinar 3 Closing the Gap in Financing Malaria Control Strategies

Closing the Gap in Financing Malaria Control Strategies

The first two webinars of the End Malaria series hosted by AFIDEP’s Platform for Dialogue and Action on Health Technologies in Africa explored concrete ideas and actions required to significantly reduce malaria on the continent as well as the threats to its elimination. The third webinar explored the role of funding and investments in realising significant milestones, emphasising the importance of sustainable financing of malaria control interventions.

Implementing comprehensive malaria control interventions is undeniably expensive. According to the 2021 update of the Global Technical Strategy for Malaria (GTSM), the estimated annual resources required to combat malaria were projected to be US$ 6.8 billion in 2020. This amount is expected to increase by US$ 0.5 billion per year, reaching US$ 9.3 billion by 2025. Subsequently, the estimated required funding would continue to rise by US$ 0.2 billion annually, ultimately reaching US$10.3 billion by 2030. Between 2021 and 2030, financing for research and development requires US$ 8.5 billion, translating to US$ 851 million annually.

The 2022 WHO World Malaria Report estimated the total funding in 2021 to be US$ 3.5 billion, up from US$ 3.3 billion in 2020 and US$ 3.0 billion in 2019. The amount invested in 2021 fell short of the estimated US$ 7.3 billion needed globally to stay on track for the GTSM target of reducing the global malaria burden by 90% by 2030. Further, in 2022, during the 7th Replenishment Conference, countries pledged US$ 15.7 billion towards the Global Fund to Fight AIDS, Tuberculosis and Malaria, falling short of the targeted US$ 18 billion. This replenishment came amidst a challenging global economic climate, and it is commendable that countries were able to raise the amount.

Nevertheless, the financial gap between the resources invested and those needed to control malaria has widened over the years, from US$ 2.6 billion in 2019 to US$ 3.5 billion in 2020, and US$ 3.8 billion in 2021. This gap jeopardises progress in combating the disease, and it is crucial to explore new financing mechanisms and strategies.

Facilitating regional and national funding and cooperation

During her keynote speech, Dr Perpetua Uhomoibhi, the Director/National Coordinator of the National Malaria Elimination Programme (NMEP) in Nigeria, emphasised the importance of implementing new financial mechanisms, including strengthening regional and national funds and establishing public-private-philanthropic partnerships, to bridge the funding gap in the fight against malaria.

Strengthening regional funds allows for the enhancement of financial resources and mechanisms available to support malaria interventions. Pooling resources of countries within the region, as well as harmonising malaria control strategies, policies and interventions across countries, can ensure that efforts are coordinated and complementary, minimise duplication of activities, and maximise the impact of interventions. Thus, regional cooperation and collaboration are vital for strengthening regional funds.

Promoting domestic resource mobilisation and manufacturing

While international funding has played a crucial role in malaria control efforts, empowering countries to take charge of their strategies and interventions for sustainable elimination is also important. In light of this, it is crucial for countries to have well-defined business and investment plans for malaria control, outlining their priorities, targets and resource requirements, as emphasised by Dr Themba Mzilahowa, Senior Entomologist at the Malaria Alert Centre, Kamuzu University of Health Sciences (KUHeS), Malawi. This will allow countries to articulate their needs better and attract domestic and international funding.

At the national level, governments must prioritise malaria control and commit to allocating a significant portion of their national budgets to combat the disease. This can be done by exploring various avenues for resource mobilisation, such as tax relief for specific industries. Domestic funds provide the flexibility to tailor malaria control interventions to specific country needs, priorities, and epidemiological profiles.

John Bawa, Director of Malaria Vaccine Implementation at PATH’s Center for Vaccine Innovation and Access, recommended that African countries strive to attain WHO prequalification status for locally manufactured products to promote domestic manufacturing of malaria drugs and commodities, including the recently approved malaria vaccine. WHO prequalification is a service offered by the WHO in which they evaluate the quality, safety, and efficacy of medicinal products, and local manufacturing of pharmaceutical products can be boosted through this prequalification. Currently, most countries in Africa heavily rely on imports of malaria commodities. Harnessing local manufacturing and reducing import dependence can promote the widespread availability of malaria vaccines.

He further noted that the successful strategies and mechanisms established for COVID-19 vaccine distribution can be utilised to facilitate the roll out of malaria vaccines. The Partnerships for African Vaccine Manufacturing Framework for Action, under the Africa Centres for Disease Control and Prevention (Africa CDC), provides guidance on how countries can coordinate and speed up domestic manufacturing, and can be a promising avenue for countries to leverage in boosting local manufacturing.

Harnessing Africa’s young population

Africa’s youthful population provides great potential to drive change and innovation in malaria control. Their energy, creativity and determination can be harnessed to generate novel ideas, mobilise communities to take action, influence policy decisions, and attract sustainable financial resources. Additionally, engaging young people builds intergenerational partnerships and a transfer of experience on malaria control, ensuring the sustainability of interventions.

The African Leaders Malaria Alliance (ALMA) Youth Advisory Council is one such strategic platform empowering youths and harnessing their potential for malaria elimination. Amb. Odinaka Kingsley Obeta, West African Lead of the ALMA Youth Advisory Council, noted that they are mandated to provide ALMA with strategic guidance on engaging young people in policy development and programme implementation. During the last Commonwealth Heads of Government Meeting (CHOGM) held in 2022, contributions by the youth council resulted in bold commitments to eliminate malaria by 2030, including financial commitments to replenish the Global Fund.

In all, the key takeaway from the discussions of the webinar is that harnessing the myriad opportunities within countries, including from the private sector, can provide widespread availability of the essential tools and products needed to end malaria in Africa.

Read summaries of the previous webinars:

Webinar 1 Zero Malaria Is Possible: Ending the Malaria Burden in Africa

Webinar 2 Navigating Africa’s Journey to Malaria Elimination: Threats and Opportunities